Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

Journal of the National Cancer Institute

Volumn 95, Issue 23, 2003, Pages 1758-1764

  Stearns, Vered ^a,c   Johnson, Michael D ^a   Rae, James ^b,d   Morocho, Alan ^b   Novielli, Antonella ^a   Bhargava, Pankaj ^a,b,e   Hayes, Daniel F ^a,d   Desta, Zeruesenay ^b   Flockhart, David A ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; ENDOXIFEN; ESTRADIOL; KETOCONAZOLE; OMEPRAZOLE; PAROXETINE; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SULFAPHENAZOLE; TAMOXIFEN; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL STRAIN MCF 7; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HOT FLUSH; HUMAN; HYDROXYLATION; IN VITRO STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION; WILD TYPE;

EID: 0346602691     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg108     Document Type: Article

References (29)

1. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
3. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
4. Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:160-5.
5. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
6. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984;25:127-205.
7. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet 2002;360:1851-61.
8. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, La Vasseur BI, Barton DL, et al. Venlafaxine in management of hot flashes in survivors of breast 0cancer: a randomised controlled trial. Lancet 2000;356:2059-63.
9. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-83.
10. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-34.
11. Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 1997;57:3402-6.
12. Crewe HK, Ellis SW, Leonard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997;53:171-8.
13. Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T, et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 2002;54:157-67.
14. Lessard E, Yessine MA, Hamelin BA, Gauvin C, Labbe L, O'Hara G, et al. Diphenhydramine, alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 2001;21:175-84.
15. Albers LJ, Reist C, Vu RL, Fujimoto K, Ozdemir V, Helmeste D, et al. Effect of venlafaxine on imipramine metabolism. Psychiatry Res 2000;96: 235-43.
16. Yoon YR, Cha IJ, Shon JH, Kim KA, Cha YN, Jang IJ, et al. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther 2000;67:567-76.
17. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997;62:334-47.
18. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
19. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51: 73-8.
20. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999;65:10-20.
21. Fried KM, Wainer IW. Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J Chromatogr B Biomed Appl, 1994;655:261-8.
22. Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 2003;791:245-53.
23. Kikuta C, Schmid R. Specific high-performance liquid chromatographic analysis of tamoxifen and its major metabolites by "on-line" extraction and post-column photochemical reaction. J Pharm Biomed Anal 1989;7:329-37.
24. Ogawa K, Matsushita Y, Yamawaki I, Kaneda M, Shibata J, Toko T, et al. Synthesis and antiestrogenic activity of the compounds related to the metabolites of (E)-4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-(4-isopropylphenyl) -1-butenyl]phenyl monophosphate (TAT-59) [corrected][published erratum appears in Chem Pharm Bull Tokyo) 1992;40:3358]. Chem Pharm Bull (Tokyo) 1991;39:911-6.
25. Desta Z, Soukhova N, Morocho AM, Flockhart DA. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A. J Pharmacol Exp Ther 2001;298:508-20.
26. Morocho A, Desta Z, Wu GW, Soukhova N, Rae J, Flockhart DA. Characterization of tamoxifen metabolism to a novel, putative active metabolite [abstract]. Clin Pharmacol Ther 2001;69:P68.
27. Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 2002;30:336-43.
28. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991;10:545-58.
29. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207-18.